Evaro, an NHS-licensed digital healthcare platform serving over two million patients, has closed a Series A funding round of around £18 million.
The platform already partners with period-tracking app Clue and sexual wellness retailer Lovehoney, embedding prescription services directly into their customer experiences.
The Norwich-based firm says the round will accelerate Evaro’s healthcare-as-a-service model across three markets: consumer brands seeking new revenue streams, healthcare organisations expanding digital capacity, and employers deploying health benefits.
Led by AlbionVC, it includes participation from Simplyhealth Ventures, Exceptional Ventures, Cornerstone VC and BBI.
The funding comes as 20.5 million people experienced month-long waits for a GP appointment in 2024, up 60% in seven years. Evaro helps alleviate the burden on the NHS by providing complete regulated healthcare infrastructure – asynchronous consultations allowing speed and discretion of care, remote diagnostics, prescribing, dispensing, and aftercare – that can be embedded into any platform people spend time on within days.
For partners, the model creates a new revenue stream with minimal implementation burden – integrations can be completed in as little as two weeks, it claims – while deepening customer relationships through an expanded health offering.
“When a third of people are waiting over a week just to see their GP, it’s time to think through alternative solutions that help people get the care they need while supporting NHS capacity,” said Dr Thuria Wenbar, CEO and co-founder.
“What we’ve built is infrastructure that allows our partners – brands people already trust – to deliver safe and regulated healthcare for common conditions without having to build a thing.
“We’re making healthcare as accessible as online banking, and this funding lets us prove that model works at scale.”
The firm was founded in 2018 by emergency physician Dr Wenbar and pharmacist researcher Dr Oskar Wenbar.
“We’ve seen embedded finance transform banking, Evaro is now driving the embedded health revolution,” said Christoph Ruedig, partner at AlbionVC, who joins Evaro’s board.
“Evaro has spent seven years building its infrastructure properly, with deep regulatory credentials. This now allows consumer brands to enter the healthcare space safely, unlocking massive latent demand while relieving pressure on the NHS. We are thrilled to back the team as they define this new category.”